Have a feature idea you'd love to see implemented?
Let us know!
MESO Mesoblast Ltd
Price (delayed)
$10.18
Market cap
$1.16B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.89
Enterprise value
$1.22B
mesoblast; (asx: msb; nasdaq:meso) is a world leader in innovative cell-based medicines. we have leveraged our proprietary technology platforms based on specialized cells known as mesenchymal lineage adult stem cells
Highlights
The EPS has increased by 15% YoY
The quick ratio fell by 39% YoY
The company's revenue fell by 21% YoY
Key stats
What are the main financial stats of MESO
Market
Valuations
Earnings
Shares outstanding
114.18M
Market cap
$1.16B
Enterprise value
$1.22B
Price to earnings (P/E)
N/A
Price to book (P/B)
2.15
Price to sales (P/S)
175.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
206.42
Revenue
$5.9M
EBIT
-$65.14M
EBITDA
-$65.14M
Free cash flow
-$48.73M
Per share
Balance sheet
Liquidity
EPS
-$0.89
Free cash flow per share
-$0.48
Book value per share
$4.73
Revenue per share
$0.06
TBVPS
$0.92
Total assets
$669.15M
Total liabilities
$188.8M
Debt
$118.92M
Equity
$480.36M
Working capital
$13.22M
Debt to equity
0.25
Current ratio
1.18
Quick ratio
1.15
Net debt/EBITDA
-0.86
Margins
Efficiency
Dividend
EBITDA margin
-1,103.7%
Gross margin
100%
Net margin
-1,490.3%
Operating margin
-952.6%
Return on assets
-13.1%
Return on equity
-17.9%
Return on invested capital
-75.9%
Return on capital employed
-10.9%
Return on sales
-1,103.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
MESO stock price
How has the Mesoblast stock price performed over time
Intraday
-1.45%
1 week
-10.07%
1 month
5.49%
1 year
320.66%
YTD
362.73%
QTD
24.6%
Financial performance
How have Mesoblast's revenue and profit performed over time
Revenue
$5.9M
Gross profit
$5.9M
Operating income
-$56.22M
Net income
-$87.96M
Gross margin
100%
Net margin
-1,490.3%
The net margin has declined by 37% year-on-year
The company's revenue fell by 21% YoY
The company's gross profit fell by 21% YoY
MESO's operating income is up by 18% year-on-year
Growth
What is Mesoblast's growth rate over time
Valuation
What is Mesoblast stock price valuation
P/E
N/A
P/B
2.15
P/S
175.04
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
206.42
The EPS has increased by 15% YoY
The stock's P/B is 115% above its last 4 quarters average of 1.0 and 54% above its 5-year quarterly average of 1.4
Mesoblast's equity has decreased by 4.3% YoY
The stock's price to sales (P/S) is 154% more than its 5-year quarterly average of 68.9 and 149% more than its last 4 quarters average of 70.4
The company's revenue fell by 21% YoY
Efficiency
How efficient is Mesoblast business performance
The ROS has decreased by 34% YoY
MESO's ROE is down by 10% year-on-year
The ROA has contracted by 7% YoY
MESO's ROIC is down by 4.5% YoY
Dividends
What is MESO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for MESO.
Financial health
How did Mesoblast financials performed over time
MESO's current ratio is down by 39% year-on-year
The quick ratio fell by 39% YoY
The debt is 75% smaller than the equity
Mesoblast's debt to equity has increased by 9% YoY
Mesoblast's equity has decreased by 4.3% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.